Golden Biotechnology Corporation
12
0
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
90.0%
+3.5% vs industry average
0%
0 trials in Phase 3/4
67%
6 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
Role: lead
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
Role: lead
A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B
Role: lead
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
Role: lead
Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Role: lead
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
Role: lead
A Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B
Role: collaborator
A Phase II, Placebo-controlled Trial Evaluating the Efficacy of Antroquinonol in Patients With Atopic Dermatitis
Role: collaborator
A Trial of Antroquinonol in Patients With Atopic Dermatitis
Role: lead
Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects
Role: lead
A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects
Role: lead
Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia
Role: lead
All 12 trials loaded